As in previous trials, immune responding patients with wild-type IDH1 (those exhibiting ≥50% increased IFNγ tumor antigen response post-vaccine without IDH1R132H) showed significantly increased progression-free survival (PFS) after DC vaccination (Fig. 1E). This evidence concerns the gene IFNG and neoplasm.